ProCE Banner Activity

Phase I Pharmacokinetic Study of Novel HIV-1 Capsid Inhibitor Lenacapavir Supports Potential for Every-6-Month SC Dosing

Slideset Download
Conference Coverage
Results demonstrate that this novel investigational first-in-class HIV-1 capsid inhibitor was generally well tolerated after single-dose administration in healthy volunteers, with PK supportive of a 6-month dosing interval.

Released: July 10, 2020

Expiration: July 09, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by:

Gilead

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

AIDS 2020

ProCE Banner

IAS 2018

ProCE Banner